PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer


Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

Related Videos
Gabriella Smith, MD
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Video 8 - "Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression"
Video 7 - "The Importance of Thyroidectomy in DTC Patient Care"
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer
Debra L. Richardson, MD, FACS, FACOG
A panel of 4 experts on colorectal cancer